A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression

NCT00044681 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder
Depressive Disorder, Major
Depression

Interventions

DRUG: risperidone

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]